A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease.
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms X-MEN
- 02 May 2016 Status changed from recruiting to completed.
- 15 Mar 2011 New trial record